• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

Raf

Items 1-50 of 135

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A10001
    Sorafenib Tosylate (Nexavar)

    Raf inhibitor

    Sorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
    Quick View
  2. A10002
    PLX-4720

    Raf inhibitor

    PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
    Quick View
  3. A10250
    Regorafenib (BAY 73-4506)

    VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
    Quick View
  4. A10420
    GDC-0879

    B-Raf inhibitor

    GDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
    Quick View
  5. A10661
    NVP-BHG712

    EphB4 inhibitor

    NVP-BHG712 is a selective inhibitor of EphB4 kinase that exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3.
    Quick View
  6. A13226
    LGX 818 (Encorafenib)

    Selective B-RAF Inhibitor

    LGX818 is an orally available Raf kinase inhibitor with potential antineoplastic activity.
    Quick View
  7. A11381
    Dabrafenib (GSK2118436A)

    Raf inhibitor

    Dabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
    Quick View
  8. A16079
    (E/Z)-Locostatin ((E/Z)-UIC-1005)

    RKIP/Raf1 inhibitor

    Locostatin is a cell permeable, potent inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.
    Quick View
  9. A10739
    PLX4032 (Vemurafenib)

    Raf inhibitor

    PLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
    Quick View
  10. A13323
    TAK-632

    pan-RAF inhibitor

    TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC50, 12 nM; pMEK (HMVII), 49 nM; V/B ratio.
    Quick View
  11. A14019
    Avutometinib (RO5126766, CH5126766)

    Raf/MEK dual inhibitor

    Avutometinib (RO5126766, CH5126766), is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-neoplastic activity.

    Quick View
  12. A12739
    PF-04880594

    RAF inhibitor

    PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.
    Quick View
  13. A12891
    Diazepinomicin

    RAS/RAF/MAPK inhibitor

    Diazepinomicin, also known as TLN-4601, is a small-molecule inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity.
    Quick View
  14. A13119
    Balamapimod (MKI-833)

    Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
    Quick View
  15. A13177
    Belvarafenib

    pan RAF inhibitor

    Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
    Quick View
  16. A11211
    ML 786 dihydrochloride

    Raf inhibitor

    ML 786 dihydrochloride is a potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively).
    Quick View
  17. A11240
    MLN2480 (BIIB-024)

    pan-Raf inhibitor

    MLN 2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.
    Quick View
  18. A11333
    BRAF inhibitor

    BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.
    Quick View
  19. A11436
    GW 5074

    Raf-1 Inhibitor

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor
    Quick View
  20. A11546
    Regorafenib Hydrochloride

    VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Quick View
  21. A12005
    Sorafenib N-Oxide

    Raf kinase inhibitor

    Sorafenib N-Oxide is a metabolite of Sorafenib, a potent Raf kinase inhibitor.
    Quick View
  22. A13525
    L-779450

    Raf inhibitor

    L-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
    Quick View
  23. A13772
    CEP-32496

    Raf inhibitor

    CEP-32496 is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity.
    Quick View
  24. A14122
    B-Raf-inhibitor 1

    B-Raf inhibitor

    B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively
    Quick View
  25. A15855
    PLX7904

    Raf inhibitor

    PLX7904 is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells.
    Quick View
  26. A16022
    HG6-64-1

    B-Raf inhibitor

    HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
    Quick View
  27. A16603
    LY3009120

    pan RAF inhibitor

    LY3009120 is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively.
    Quick View
  28. A16840
    PLX8394

    BRAF inhibitor

    PLX8394 is a next-generation, orally available, small-molecule BRAF inhibitor with IC50 values of 3.8 nM, 14 nM and 23 nM for BRAF(V600E), WT BRAF and CRAF respectively. It has potential antineoplastic activity.
    Quick View
  29. A16841
    LXH254

    pan-RAF inhibitor

    LXH254 is a type II ATP-competitive inhibitor that inhibits both B- and CRAF kinase activities at picomolar concentrations with a high degree of selectivity against a panel of 456 human kinases and in cell-based assays.
    Quick View
  30. A16842
    RAF709

    raf kinase inhibitor

    RAF709 is a potent inhibitor of B/C RAF kinase with almost equivalent IC50 values of 0.4 nM for B-RAF and C-RAF, showing a high level of selectivity, demonstrating greater than 99% on-target binding to BRAF, BRAFV600E, and CRAF at 1 μM and very few off-targets with DDR1 (>99%), DDR2 (86%), FRK (92%), and PDGFRb (96%), the only kinases with binding >80% at 1 μM.
    Quick View
  31. A16844
    Lifirafenib (BGB-283)

    BRAF inhibitor

    Lifirafenib (BGB-283), also known as Beigene-283, potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
    Quick View
  32. A20988
    rel-Lifirafenib

    Raf/EGFR inhibitor

    Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
    Quick View
  33. A21055
    B-Raf IN 1

    B-Raf kinase inhibitor

    B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC50 of 24 nM.
    Quick View
  34. A21489
    Sorafenib (D3)

    Raf/VEGFR3 inhibitor

    Sorafenib D3 (Bay 43-9006 D3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  35. A21495
    Sorafenib (D4)

    Raf/VEGFR3 inhibitor

    Sorafenib D4 (Bay 43-9006 D4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  36. A19734
    BI-882370

    RAF inhibitor

    BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase.
    Quick View
  37. A19011
    RAF mutant-IN-1

    Raf nhibitor

    RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF340D/Y341D, B-RAFV600E and B-RAFWT, respectively.
    Quick View
  38. A19080
    Rineterkib (ERK-IN-1)

    RAF/ERK1/2 inhibitor

    Rineterkib (ERK-IN-1) (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.

    Quick View
  39. A19449
    LUT014

    B-Raf inhibitor

    LUT014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .
    Quick View
  40. A15040
    CEP-32496 hydrochloride

    Raf Inhibitor

    CEP-32496 hydrochloride is a highly potent inhibitor of wild-type BRAF, V600E mutant BRAF and c-Raf with Kd values of 14 nM, 36 nM and 39 nM, respectively.
    Quick View
  41. A15059
    Dabrafenib Mesylate

    Raf inhibitor

    Dabrafenib Mesylate is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
    Quick View
  42. A15218
    Regorafenib monohydrate

    Tyrosine kinase inhibitor

    Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
    Quick View
  43. A17225
    AZ304

    dual BRAF inhibitor

    AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF. AZ304 exerted potent inhibitory effects on both wild type and V600E mutant forms of the serine/threonine-protein kinase BRAF, with IC50 values of 79?nM and 38?nM, respectively.
    Quick View
  44. A17524
    Rafoxanide

    Antiparasitic

    Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infestations.
    Quick View
  45. A17857
    Sorafenib

    Raf/VEGFR3 inhibitor

    Sorafenib (Bay 43-9006) is a potent, orally active multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  46. A30711
    RRD-251

    Rb-Raf-1 Inhibitor

    RRD-251 is a selective inhibitor of the retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction. This compound exhibits potent anti-proliferative, anti-angiogenic, and anti-tumor activities, making it valuable for research focused on cancer biology and therapeutic strategies targeting cell growth and tumor progression. Its ability to disrupt this critical protein interaction highlights its potential use in studies investigating the molecular mechanisms underlying various cancers.
    Quick View
  47. A33462
    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose

    FGFR3/BRAF Binder

    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose functions as a selective binder for Fibroblast Growth Factor Receptor 3 (FGFR3) and BRAF, playing a pivotal role in modulating pathways associated with cancer progression. Derived from Atractylodes japonica, this compound exhibits low cytotoxicity towards cancer cell lines, making it a suitable candidate for research applications focused on targeted cancer therapies and signaling pathway studies. Its unique structural characteristics enhance its potential for further exploration in drug development and therapeutic interventions.
    Quick View
  48. A36787
    CG 858-Neg

    BRAF PROTACs Negative Control

    CG 858-Neg is a negative control for Thalidomide-derived PROTAC degraders targeting BRAF and BRAFV600E, exhibiting Ki values of 9.5 nM and 14.4 nM, respectively. This compound effectively inhibits downstream phosphorylation of ERK and demonstrates suppression of BRAFV600E-driven tumorigenesis in melanoma (A375 cells, IC50 = 492 nM) and colorectal cancer (HT-29 cells, IC50 = 459 nM) models. CG 858-Neg is suitable for research applications focused on the mechanisms of melanoma and colorectal carcinoma.
    Quick View
  49. A36638
    Cefotetan

    hRKIP-Raf1 Inhibitor

    Cefotetan is a selective inhibitor of the human Raf1 kinase inhibitor protein (hRKIP). By binding to hRKIP, Cefotetan reduces its interaction with Raf1 kinase, thereby alleviating the inhibition of the Ras/Raf1/MEK/ERK signaling pathway and facilitating enhanced ERK phosphorylation. This mechanism makes Cefotetan valuable for research on diseases linked to dysregulated signaling within this pathway. Additionally, Cefotetan functions as a broad-spectrum antibacterial agent by binding to bacterial penicillin-binding proteins (PBPs) and disrupting cell wall synthesis, making it useful for investigating bacterial infections, particularly in the contexts of bone, skin, urinary tract, and lower respiratory tract infections.
    Quick View
  50. A36648
    Tinlorafenib

    BRAF Kinase Inhibitor

    Tinlorafenib is a potent inhibitor of BRAF and CRAF kinases, exhibiting IC50 values of 5.8 nM and 4.1 nM, respectively. It specifically targets V600E and V600K mutations in BRAF with IC50s of 4.25 nM and 2.7 nM, making it valuable for studying BRAF-driven tumors. Notably, Tinlorafenib demonstrates effective penetration of the blood-brain barrier, facilitating research into both central nervous system tumors and extracranial malignancies associated with BRAF mutations.
    Quick View

Items 1-50 of 135

Page
per page
Set Descending Direction
Shop By
Shopping Options